Novel Therapeutic Approaches for Diffuse Large B-cell Lymphoma
The Diffuse Large B-cell Lymphoma treatment spectrum has expanded significantly in recent years, particularly for patients with relapsed or refractory (R/R) disease. Many prominent players are working on developing therapies to improve the condition.
Los Angeles, USA , Feb. 03, 2021 (GLOBE NEWSWIRE) —Novel Therapeutic Approaches for Diffuse Large B-cell LymphomaThe Diffuse Large B-cell Lymphoma treatment spectrum has expanded significantly in recent years, particularly for patients with relapsed or refractory (R/R) disease. Many prominent players are working on developing therapies to improve the condition.
DelveInsight’s, “Diffuse Large B Cell Lymphoma (DLBCL) Pipeline Insight” report provides comprehensive insights about100+companies and100+pipeline drugs in the Diffuse Large B Cell Lymphoma pipeline landscape. It comprises DLBCL pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diffuse Large B Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights the inactive DLBCL pipeline products.
Some of the significantDiffuse Large B Cell Lymphoma Pipeline Report
Highlights
- Several prominent companies such as ADC Therapeutics, BeiGene, Nordic Nanovector, bluebird bio, Celgene, GlaxoSmithKline, AbbVie, Roche and many others are working to assess challenges and seek opportunities that could influence Diffuse Large B-cell Lymphoma R&D. The DLBCL pipeline therapies are focused on novel approaches for the treatment.
- Different therapies which are used include Cytotoxic therapies, Antibodies- Bispecific antibodies, Antibody-Drug Conjugates, CAR therapies, Targeted therapies- Immunomodulating Agents, Proteasome Inhibitors, Phosphatidylinositol 3-Kinase (PI3K) Pathway, Cell Death, Kinase Inhibitors, JAK/STAT Pathway, Toll-Like Receptor (TLR) Agonist, Heat Shock Proteins.
- In September 2020, ADC Therapeuticssubmitted a Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma.
- In September 2020,ADC Therapeuticswas planning to initiate a phase III randomized study of Loncastuximab Tesirine combined with rituximab versus immunochemotherapy in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). The trial is expected to be completed in December 2024.
- ADC Therapeutics and Freenomein August 2019,announced that they have entered a biomarker development collaboration in which ADC Therapeutics will use Freenome’s platform to identify patients who are most likely to respond to treatment with ADCT-402 (loncastuximab tesirine).
- In August 2018,ADC Therapeuticsinitiated a phase II open-label single-arm study to evaluate the efficacy and safety of Loncastuximab Tesirine in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). The trial is expected to be completed in March 2021.
- Loncastuximab tesirinewas granted orphan drug designation by the US FDA in June 2017 for the diffuse large B-cell lymphoma treatment.
Request for sample pages @Diffuse Large B Cell Lymphoma Pipeline Therapeutics
Diffuse Large B Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections.DLBCL is usually treated with a number of different chemotherapy drugs, a steroid and a targeted immunotherapy drug called rituximab (Mabthera). This combination is called chemoimmunotherapy. There are different combinations. One of the main combinations is R-CHOP. This includes the drugs rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone.
- Loncastuximab tesirine by ADC Therapeutics
Loncastuximab tesirineis an antibody-drug conjugate (ADC) that is composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. CD19 is a clinically validated target for the treatment of B-cell malignancies. Loncastuximab tesirine is being assessed in a pivotalPhase 2clinical trial in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, a Phase 1b trial in combination with ibrutinib in patients with R/R DLBCL or mantle cell lymphoma (MCL) and a Phase 1b trial in combination with durvalumab in patients with R/R DLBCL, MCL or follicular lymphoma. January 2020,ADC Therapeutics stated positive results from the pivotal 145-patient Phase II clinical trial of loncastuximab tesirine (ADCT-402) to treat relapsed or refractory DLBCL.
For further product profiles, request @Diffuse Large B Cell Lymphoma Pipeline Landscape
Scope ofDLBCL Pipeline Drug Insight
- Coverage:Global
- Major Players:100+Key Companies
- Prominent Players:ADC Therapeutics, BeiGene, Nordic Nanovector, bluebird bio, Celgene, GlaxoSmithKline, AbbVie, Roche and many others.
- Key Drugs Profiles: 100+Products
- Phases:
- Diffuse Large B-cell Lymphoma Therapies Late-stage (Phase III)
- Diffuse Large B-cell Lymphoma Therapies (Phase II)
- Diffuse Large B-cell Lymphoma Therapies (Phase I)
- Diffuse Large B-cell Lymphoma Therapies Pre-clinical stage and Discovery candidates
- Discontinued and Inactive candidates
- Molecule Types:
- Small molecule
- Gene therapy
- Stem cell therapy
- Mechanism of Action:
- Protease inhibitors
- Immunomodulatory
- Multiple kinase inhibitor
- Route of Administration:
- Oral
- Inhalation
- Subcutaneous
- Intravenous
- Targets:
- Protease
- Immune System
- Multiple kinases
- Product Types:
- Monotherapy
- Combination
Key Questions regarding CurrentDiffuse Large B-cell Lymphoma Treatment Landscapeand Emerging Therapies Answered in the Pipeline Report
- What are the current options for Diffuse Large B-cell Lymphoma treatment?
- How many companies are developing therapies for the treatment of DLBCL?
- How many Diffuse Large B-cell Lymphoma emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of DLBCL?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Diffuse Large B-cell Lymphoma market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of DLBCL?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Diffuse Large B-cell Lymphoma therapies?
- What are the key designations that have been granted for the emerging therapies for DLBCL?
- How many patents are granted and pending for the emerging therapies for the treatment of Diffuse Large B-cell Lymphoma?
Table of Contents
| 1 | Diffuse Large B-cell Lymphoma Introduction |
| 2 | DLBCL Executive Summary |
| 3 | Diffuse Large B-cell Lymphoma Overview |
| 4 | DLBCL Analytical Perspective In-depth Commercial Assessment |
| 5 | Diffuse Large B-cell Lymphoma Pipeline Therapeutics |
| 5.1 | Diffuse Large B-cell Lymphoma Late Stage Products (Phase III) |
| 5.1.1 | Loncastuximab tesirine: ADC Therapeutics |
| 5.2 | Diffuse Large B-cell Lymphoma Mid Stage Products (Phase II) |
| 5.2.1 | BGB-3111: BeiGene |
| 5.3 | Diffuse Large B-cell Lymphoma Early Stage Products (Phase I) |
| 5.3.1 | 177Lu-DOTA-HH1: Nordic Nanovector |
| 6 | DLBCL Preclinical Stage and Discovery Stage Products |
| 6.1 | Research programme: chimeric antigen T-cell therapies – bluebird bio |
| 7 | Diffuse Large B-cell Lymphoma Therapeutic Assessment |
| 8 | DLBCL Inactive Products |
| 9 | Company-University Collaborations (Licensing/Partnering) DLBCL Analysis |
| 10 | Diffuse Large B-cell Lymphoma Key Companies |
| 11 | DLBCL Key Products |
| 12 | Diffuse Large B-cell Lymphoma Unmet Needs |
| 13 | DLBCL Market Drivers and Barriers |
| 14 | Diffuse Large B-cell Lymphoma Future Perspectives and Conclusion |
| 15 | DLBCL Analyst Views |
| 16 | Appendix |
| 17 | About DelveInsight |
Get customised pipeline report @DLBCL Pipeline Insight Report
Related Reports
DelveInsight’s Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s Diffuse Large B-cell Lymphoma – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Diffuse Large B-cell Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight’s Relapsed Chronic Lymphocytic Leukemia (CLL) – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s ATCL Market report 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market trends in 7MM.
DelveInsight’s Indolent Lymphoma – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2030 report provides a detailed understanding of historical and forecasted epidemiology.
DelveInsight’s Basal Cell Carcinoma (Basal Cell Epithelioma) – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s Kaposi’s Sarcoma Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of the disease & an understanding of historical and forecasted epidemiology.
DelveInsight’s Oligodendroglioma – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s Chronic Inducible Urticaria Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s Corneal Ulcer – Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
About
DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact Us:Shruti Thakur [email protected] +1(919)321-6187 www.delveinsight.com
